SCHEMBL2260888

SCHEMBL2260888

Cc1cccc(CCNC(=O)COc2cc(C(F)(F)F)nn2-c2ccccc2Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ MAPT P10636 3/20 0.43
▸ TGFBR1 P36897 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NPY1R P25929 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ CARM1 Q86X55 1/20 0.40
▸ GLA P06280 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HDAC3 O15379 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ HDAC10 Q969S8 1/20 0.39
▸ HDAC11 Q96DB2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2256572 0.91 ALDH1A1 (0.43) MAPTTGFBR1ALDH1A1MEN1KMT2A
SCHEMBL2257644 0.91 POLB (0.45) TGFBR1CARM1POLBTSHRTRPV1
SCHEMBL2258277 0.91 GLA (0.48) SMN1; SMN2MAPTTGFBR1ALDH1A1MAPK1
SCHEMBL2258069 0.91 CA1 (0.47) TGFBR1ALDH1A1MEN1KMT2AGLA
SCHEMBL2256123 0.88 TRPV1 (0.44) SMN1; SMN2MAPTTGFBR1ALDH1A1MAPK1
SCHEMBL2259409 0.87 TGFBR1 (0.41) SMN1; SMN2MAPTTGFBR1ALDH1A1MEN1
SCHEMBL2260391 0.87 TGFBR1 (0.43) SMN1; SMN2MAPTTGFBR1ALDH1A1LMNA
SCHEMBL2256786 0.86 ALDH1A1 (0.52) SMN1; SMN2MAPTTGFBR1ALDH1A1MEN1
SCHEMBL2255860 0.86 TGFBR1 (0.42) MAPTTGFBR1ALDH1A1LMNATP53
SCHEMBL2256142 0.86 ALDH1A1 (0.42) MAPTTGFBR1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121621-B1 LXR AND FXR MODULATORS EXELIXIS PATENT CO LLC (US) 2014-05-07 — — EP disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069367-A1 LXR and FXR Modulators NR1H3, NR1H2, NR1H4 SMN1; SMN2 4725/4885MAPT 4713/4885TGFBR1 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback